Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline alphoscerate + nimodipine pilot study in subcortical vascular cognitive impairment
2015-003188-13Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subcortical vascular cognitive impairment (SVCI) comparing Choline alphoscerate + nimodipine with Nimodipine + placebo (2 arms). Primary endpoint: Cognitive decline. Started Feb 2022; status: terminated.
02
Drugs
choline alfosceratenimodipine
03
Conditions
subcortical vascular cognitive impairment (SVCI)
Beyond the preview
Go deeper on 2015-003188-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003188-13.